Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash

$TWST
$XOMA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $TWST alert in real time by email

Twist to retain all upfront, service and other revenue earned under antibody discovery and biopharma solutions agreements as well as half of future milestones and royalties

Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has entered into a royalty purchase agreement with XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator.

Under the terms of the agreement, XOMA Royalty will provide Twist Bioscience an upfront payment of $15 million in cash in exchange for the right to receive half of the future potential milestone and royalty payments resulting from existing antibody discovery and biopharma services collaborations with Twist's partners. Twist will retain all upfront, service and other revenue earned under its antibody discovery and biopharma services collaborations as outlined in the applicable agreements. In addition, Twist retains full rights to any future biopharma collaborations that include milestone and royalty terms. The agreement does not apply to any synbio, NGS, or data storage revenue.

"This unique agreement provides Twist Bioscience with capital today that will add to our balance sheet and enable continued innovation for profitable growth across the company," said Emily M. Leproust, Ph.D., CEO and cofounder of Twist Bioscience. "XOMA Royalty's proven expertise in early-stage royalty monetization makes them an ideal partner for this venture."

"This collaboration with Twist Bioscience exemplifies our commitment to supporting high-potential biotech companies," commented Brad Sitko, chief investment officer of XOMA Royalty. "By acquiring a portion of Twist's milestone and royalty rights, we're contributing to their immediate growth and positioning XOMA Royalty to benefit from their established success in biopharma."

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on LinkedIn | X | YouTube | Instagram

Twist Bioscience Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements with respect to potential milestone and royalty payments resulting from existing antibody discovery and biopharma services collaborations with Twist Bioscience partners, rights to milestone and royalty terms under any future Twist Bioscience biopharma collaborations and Twist Bioscience's ability to innovate to achieve profitable growth. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to achieve the expected benefits of Twist Bioscience's restructuring activities and reduced investments in DNA data storage; the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist Bioscience to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability, which will depend heavily on the success of its existing products and the development and commercialization of additional products in the synthetic biology, biologic drug and data storage industries; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties about the retention of significant customers; the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits from acquisitions; supply chain and other disruptions; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience's patents or proprietary rights; and the risk that Twist Bioscience's proprietary rights may be insufficient to protect its technologies. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience's business in general, see Twist Bioscience's risk factors set forth in Twist Bioscience's Annual Report on Form 10-K filed with the SEC on November 21, 2023, and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Get the next $TWST alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Q&A

New
  • What recent agreement did Twist Bioscience Corporation announce?

    Twist Bioscience has entered into a royalty purchase agreement with XOMA Royalty Corporation, allowing them to retain upfront payments and future revenues while sharing future milestone and royalty payments.

  • How much upfront payment is Twist Bioscience receiving under the agreement with XOMA?

    Twist Bioscience will receive an upfront payment of $15 million from XOMA Royalty in exchange for half of its future milestone and royalty payments.

  • What revenues does Twist Bioscience retain according to the agreement?

    The agreement allows Twist to retain all upfront, service, and other revenue from its collaborations, and it does not apply to revenues from synthetic biology, NGS, or data storage.

  • What did Twist Bioscience's CEO say regarding the benefits of the agreement?

    Emily M. Leproust, the CEO of Twist Bioscience, stated that this unique agreement will provide immediate capital to support innovation and growth.

  • What position does Twist Bioscience hold in the synthetic biology and genomics industry?

    Twist is recognized as a leading synthetic biology and genomics company that has developed a DNA synthesis platform with the goal of industrializing biology engineering.

Recent Analyst Ratings for
$TWST
$XOMA

CompanyDatePrice TargetRatingAnalyst
12/13/2024$60.00Outperform
Wolfe Research
6/4/2024$53.00Buy
Guggenheim
4/29/2024$40.00Outperform
Leerink Partners
1/17/2024$25.00 → $45.00Neutral → Buy
Goldman
9/27/2023$27.00Buy
Berenberg
1/5/2023$33.00Sector Outperform
Scotiabank
1/3/2023$28.00 → $36.00In-line → Outperform
Evercore ISI
3/2/2022Outperform
Cowen
More analyst ratings

$TWST
$XOMA
Press Releases

Fastest customizable press release news feed in the world

See more
  • XOMA Royalty Declares Quarterly Preferred Stock Dividends

    EMERYVILLE, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ:XOMAP) shall receive a cash dividend equal to $0.53906 per share.  Holders of depositary shares, each representing 1/1000 of a share of XOMA Royalty's 8.375% Series B Cumulative Perpetual Preferred Stock (NASDAQ:XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share. The preferred dividends will be paid on or about April 15, 2025, to respe

    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Twist Bioscience Offers Clonal Genes for Global Academic Researchers at Express Speed for No Extra Cost

    — Supports Acceleration of Research Across Multiple Industries; Maximizes Budget — Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that, for a limited time, all Twist Express Genes orders placed by academic customers globally will be shipped in as few as four days* without incurring a premium for the rapid turnaround time. "At Twist, we recognize the increasing challenge within colleges, universities and research institutions to securing research funding and appreciate that scientific progress must continue unhindered, as Science Doesn't Stop," said Emily M. Leproust, Ph.D.,

    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Twist Bioscience to Present at Upcoming Investor Conferences

    Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that its executives will participate in fireside chats at the following upcoming investor conferences: Emily Leproust, Ph.D., CEO and co-founder, and Adam Laponis, CFO, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4 in Boston, MA; fireside chat at 1:50 pm Eastern Time Patrick Finn, Ph.D., president and COO, and Adam Laponis, CFO, will participate in a fireside chat at the Leerink Global Biopharma Conference 2025 on Tuesday, March 11 in Miami, FL; fireside chat at 9:

    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$TWST
$XOMA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$TWST
$XOMA
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$TWST
$XOMA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$TWST
$XOMA
SEC Filings

See more

$TWST
$XOMA
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • March 26, 2021 - Coronavirus (COVID-19) Update: March 26, 2021

    For Immediate Release: March 26, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On March 23, 2021, the FDA issued an emergency use authorization (EUA) to the Twist Bioscience Corporation for their SARS-CoV-2 NGS Assay. The SARS-CoV-2 NGS Assay is a next-generation sequencing (NGS) based test for the identification of SARS-CoV-2 RNA from respirato

    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$TWST
$XOMA
Leadership Updates

Live Leadership Updates

See more
  • Twist Bioscience Appoints Mike Fero, Ph.D., as Chief Information Officer

    Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mike Fero, Ph.D., as chief information officer. Dr. Fero brings more than 30 years of experience leading startups, developing commercial software, researching biology and physics and working in fast-paced deep-tech businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241008118663/en/Mike Fero, Ph.D., CIO of Twist Bioscience (Photo: Business Wire) "Mike's extensive background in building and configuring scalable enterprise softwar

    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

    Earned $9 million milestone upon U.S. Food and Drug Administration's approval of Day One's OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired Kinnate Pharmaceuticals, adding at least $9.5 million in non-dilutive capital to XOMA's balance sheet Expanded the commercial royalty and milestone portfolio with the acquisitions of economic interests in DSUVIA® (sufentanil sublingual tablet) and XACIATO™ (clindamycin phosphate) vaginal gel 2%, as well as two Phase 3 assets Launched XOMA's first stock repurchase program for up to $50 million EMERYVILLE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royal

    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Actym Therapeutics Appoints Thomas Smart as CEO

    BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical evaluation of its lead candidate, ACTM-838, later this year.

    $ANAB
    $PGEN
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$TWST
$XOMA
Financials

Live finance-specific insights

See more
  • XOMA Royalty Declares Quarterly Preferred Stock Dividends

    EMERYVILLE, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ:XOMAP) shall receive a cash dividend equal to $0.53906 per share.  Holders of depositary shares, each representing 1/1000 of a share of XOMA Royalty's 8.375% Series B Cumulative Perpetual Preferred Stock (NASDAQ:XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share. The preferred dividends will be paid on or about April 15, 2025, to respe

    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Twist Bioscience Announces Fiscal 2025 First Quarter Financial Results

    Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the first quarter fiscal 2025 ended December 31, 2024. Visit the Events and Presentations page of the Investor Relations section under the "Company" tab at www.twistbioscience.com to view the detailed fiscal first quarter 2025 earnings report and the investor presentation, or click https://investors.twistbioscience.com/events-and-presentations. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time today to discuss it

    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Twist Bioscience to Report Fiscal 2025 First Quarter Financial Results on Monday, February 3, 2025

    Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it will issue its financial results for the fiscal 2025 first quarter ended December 31, 2024, before the opening of the market on February 3, 2025. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to the conference call through the

    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$TWST
$XOMA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more